Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Holdings Boosted by Checkpoint Capital L.P.

Checkpoint Capital L.P. increased its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 71.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,504,307 shares of the company’s stock after buying an additional 629,307 shares during the quarter. Phathom Pharmaceuticals comprises 13.5% of Checkpoint Capital L.P.’s holdings, making the stock its 3rd largest position. Checkpoint Capital L.P.’s holdings in Phathom Pharmaceuticals were worth $27,198,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Huntington National Bank lifted its holdings in shares of Phathom Pharmaceuticals by 62.2% in the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after acquiring an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares during the last quarter. US Bancorp DE lifted its stake in Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after purchasing an additional 1,166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Phathom Pharmaceuticals by 42.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after buying an additional 2,987 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Phathom Pharmaceuticals in the third quarter worth about $197,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PHAT. HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Monday, August 12th. The Goldman Sachs Group increased their price objective on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, September 13th.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ:PHAT opened at $8.83 on Monday. Phathom Pharmaceuticals, Inc. has a 1 year low of $6.07 and a 1 year high of $19.71. The company has a market cap of $603.77 million, a PE ratio of -1.56 and a beta of 0.72. The stock’s 50-day moving average is $14.68 and its 200 day moving average is $13.31.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.